Abstract
Introduction: Coronary slow flow phenomena (CSFP) are associated with endothelial and blood component abnormalities in coronary arteries. Asymmetric dimethylarginine (ADMA) can damage the endothelium of the heart or blood vessels in patients with non-valvular atrial fibrillation (NVAF), causing changes in levels of biological indicators. Our aim was to analyze the relationship between ADMA and CSFP in NVAF patients. Methods: We consecutively enrolled 134 patients diagnosed with NVAF and underwent coronary angiography, 50 control patients without a history of atrial fibrillation and with normal coronary angiographic flow were included at the same time. Based on the corrected TIMI frame count (CTFC), the NVAF patients were categorized into two groups, CTFC ≤27 frames and CTFC >27 frames. Plasma ADMA, P-selectin (p-sel), von Willebrand factor (vWF), D-dimer (D-Di), plasminogen activator inhibitor 1 (PAI-1), and nitric oxide (NO) were detected by ELISA in the different groups. Results: We found that plasma ADMA levels were significantly higher among NVAF patients in the CTFC >27 grade group compared with the control or CTFC ≤27 group. In addition, the levels of blood cells and endothelium-related biomarkers (NO, P-selectin, vWF, D-Di, and PAI-1) were significantly altered and correlated with ADMA levels. Multifactorial analysis showed that plasma ADMA (odd ratio [OR; 95% CI]: 1.65 [1.21–2.43], p < 0.001) and left atrial internal diameter (OR [95% CI]: 1.04 [1.02, 1.1], p < 0.001) could be used as independent risk factors for the development of CSFP in patients with NVAF. The ROC curves of ADMA can predict the development of CSFP in NVAF patients. The minimum diagnostic concentration for the development of CSFP in patients was 2.31 µmol/L. Conclusion: Our study demonstrated that CSFP in NVAF patients was associated with high levels of ADMA and left atrial internal diameter. Therefore, aggressive preoperative detection and evaluation of ADMA and left atrial internal diameter can help deal with the intraoperative presence of CSFP.
Journal Section:
CAD and AMI: Research Article
References
1.
Rahman
H
, Demir
OM
, Khan
F
, Ryan
M
, Ellis
H
, Mills
MT
, et al. Physiological stratification of patients with angina due to coronary microvascular dysfunction
. J Am Coll Cardiol
. 2020
;75
(20
):2538
–49
. .2.
Zhu
Q
, Wang
S
, Huang
X
, Zhao
C
, Wang
Y
, Li
X
, et al. Understanding the pathogenesis of coronary slow flow: recent advances
. Trends Cardiovasc Med
. 2022
. .3.
Wang
X
, Geng
LL
, Nie
SP
. Coronary slow flow phenomenon: a local or systemic disease
. Med Hypotheses
. 2010
;75
(3
):334
–7
. .4.
Okawa
K
, Miyoshi
T
, Tsukuda
S
, Hara
S
, Matsuo
N
, Nishibe
N
, et al. Differences in endothelial dysfunction induced by paroxysmal and persistent atrial fibrillation: insights from restoration of sinus rhythm by catheter ablation
. Int J Cardiol
. 2017
;244
:180
–5
. .5.
Watson
T
, Shantsila
E
, Lip
GY
. Mechanisms of thrombogenesis in atrial fibrillation: virchow's triad revisited
. Lancet
. 2009
;373
(9658
):155
–66
. .6.
Liu
H
, Qu
X
, Liang
Z
, Chen
W
, Xia
W
, Song
Y
. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs
. Biochem Biophys Res Commun
. 2008
;377
(3
):884
–8
. .7.
Böger
RH
. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
. Cardiovasc Res
. 2003
;59
(4
):824
–33
. .8.
Polovina
MM
, Lip
GY
, Potpara
TS
. Endothelial (dys)function in lone atrial fibrillation
. Curr Pharm Des
. 2015
;21
(5
):622
–45
. .9.
Gibson
CM
, Cannon
CP
, Daley
WL
, Dodge
JT
Jr, Alexander
B
Jr, Marble
SJ
, et al. TIMI frame count: a quantitative method of assessing coronary artery flow
. Circulation
. 1996
;93
(5
):879
–88
. .10.
Beltrame
JF
. Defining the coronary slow flow phenomenon
. Circ J
. 2012
;76
(4
):818
–20
. .11.
Roshanravan
N
, Shabestari
AN
, Alamdari
NM
, Ostadrahimi
A
, Separham
A
, Parvizi
R
, et al. A novel inflammatory signaling pathway in patients with slow coronary flow: NF-κB/IL-1β/nitric oxide
. Cytokine
. 2021
;143
:155511
. .12.
Lu
TM
, Ding
YA
, Lin
SJ
, Lee
WS
, Tai
HC
. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
. Eur Heart J
. 2003
;24
(21
):1912
–9
. .13.
Grobler
C
, Maphumulo
SC
, Grobbelaar
LM
, Bredenkamp
JC
, Laubscher
GJ
, Lourens
PJ
, et al. Covid-19: the rollercoaster of fibrin(ogen), D-dimer, von Willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes
. Int J Mol Sci
. 2020
;21
(14
):5168
. .14.
Gökçe
M
, Kaplan
S
, Tekelioğlu
Y
, Erdoğan
T
, Küçükosmanoğlu
M
. Platelet function disorder in patients with coronary slow flow
. Clin Cardiol
. 2005
;28
(3
):145
–8
. .15.
Scridon
A
, Girerd
N
, Rugeri
L
, Nonin-Babary
E
, Chevalier
P
. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients
. Europace
. 2013
;15
(11
):1562
–6
. .16.
Mondillo
S
, Sabatini
L
, Agricola
E
, Ammaturo
T
, Guerrini
F
, Barbati
R
, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation
. Int J Cardiol
. 2000
;75
(2–3
):227
–32
. .17.
Lim
HS
, Willoughby
SR
, Schultz
C
, Gan
C
, Alasady
M
, Lau
DH
, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm
. J Am Coll Cardiol
. 2013
;61
(8
):852
–60
. .18.
Xia
W
, Wang
Y
, Duan
T
, Rong
Y
, Chi
Y
, Shao
Y
. Asymmetric dimethylarginine predicts left atrial appendage thrombus in patients with non-valvular atrial fibrillation
. Thromb Res
. 2015
;136
(6
):1156
–9
. .19.
Chao
TF
, Lu
TM
, Lin
YJ
, Tsao
HM
, Chang
SL
, Lo
LW
, et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram
. PLoS One
. 2013
;8
:e71675
. .20.
Ozüyaman
B
, Grau
M
, Kelm
M
, Merx
MW
, Kleinbongard
P
. Rbc NOS: regulatory mechanisms and therapeutic aspects
. Trends Mol Med
. 2008
;14
(7
):314
–22
. .21.
Camsarl
A
, Pekdemir
H
, Cicek
D
, Polat
G
, Akkus
MN
, Döven
O
, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow
. Circ J
. 2003
;67
(12
):1022
–8
. .22.
Neubauer
K
, Zieger
B
. Endothelial cells and coagulation
. Cell Tissue Res
. 2022
;387
(3
):391
–8
. .23.
Dutta
U
, Sinha
A
, Demir
OM
, Ellis
H
, Rahman
H
, Perera
D
. Coronary slow flow is not diagnostic of microvascular dysfunction in patients with angina and unobstructed coronary arteries
. J Am Heart Assoc
. 2023
;12
(1
):e027664
. .24.
Augustine
MS
, Rogers
LK
. Measurement of arginine metabolites: regulators of nitric oxide metabolism
. Curr Protoc Toxicol
. 2013
;58
(1
). Unit 17.16. .25.
Vischer
UM
. von Willebrand factor, endothelial dysfunction, and cardiovascular disease
. J Thromb Haemost
. 2006
;4
(6
):1186
–93
. .26.
Smeets
M
, Mourik
MJ
, Niessen
H
, Hordijk
PL
. Stasis promotes erythrocyte adhesion to von Willebrand factor
. Arterioscler Thromb Vasc Biol
. 2017
;37
(9
):1618
–27
. .27.
Marín
F
, Roldán
V
, Climent
VE
, Ibáñez
A
, García
A
, Marco
P
, et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
. Heart
. 2004
;90
(10
):1162
–6
. .28.
Lip
GY
, Conway
DS
. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage
. J Am Coll Cardiol
. 2001
;38
(7
):2133
–5
. .29.
Tvaroška
I
, Selvaraj
C
, Koča
J
. Selectins-the two dr. Jekyll and mr. Hyde faces of adhesion molecules-A review
. Molecules
. 2020
;25
(12
):2835
. .30.
Blann
AD
, Nadar
SK
, Lip
GY
. The adhesion molecule P-selectin and cardiovascular disease
. Eur Heart J
. 2003
;24
:2166
–79
. .31.
Guo
L
, Sun
G
, Wang
G
, Ning
W
, Zhao
K
. Soluble P-selectin promotes acute myocardial infarction onset but not severity
. Mol Med Rep
. 2015
;11
(3
):2027
–33
. .32.
Weitz
JI
, Fredenburgh
JC
, Eikelboom
JW
. A test in context: D-dimer
. J Am Coll Cardiol
. 2017
;70
(19
):2411
–20
. .33.
Lominadze
D
, Tsakadze
N
, Sen
U
, Falcone
JC
, D'Souza
SE
. Fibrinogen and fragment D-induced vascular constriction
. Am J Physiol Heart Circ Physiol
. 2005
;288
(3
):H1257
–64
. .34.
Wu
N
, Chen
X
, Cai
T
, Wu
L
, Xiang
Y
, Zhang
M
, et al. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis
. Can J Cardiol
. 2015
;31
(3
):278
–86
. .35.
Altalhi
R
, Pechlivani
N
, Ajjan
RA
. PAI-1 in diabetes: pathophysiology and role as a therapeutic target
. Int J Mol Sci
. 2021
:22
.36.
Tilly
MJ
, Geurts
S
, Pezzullo
AM
, Bramer
WM
, de Groot
NMS
, Kavousi
M
, et al. The association of coagulation and atrial fibrillation: a systematic review and meta-analysis
. Europace
. 2023
;25
(1
):28
–39
. .37.
Wijffels
MC
, Kirchhof
CJ
, Dorland
R
, Allessie
MA
. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
. Circulation
. 1995
;92
(7
):1954
–68
. .38.
Li
J
, Wang
Y
, Zhao
C
, Zhu
Q
, Li
G
, Yang
J
, et al. Incremental value of three-dimensional echocardiography for evaluating left atrial function in patients with coronary slow flow phenomenon: a case control study
. Cardiovasc Ultrasound
. 2020
;18
(1
):6
. .39.
Xing
Y
, Chen
Y
, Liu
Y
, Kong
D
, Yan
Y
, Shu
X
, et al. Evaluation of left atrial volume and function in patients with coronary slow flow phenomenon using real-time three-dimensional echocardiography
. Int J Cardiovasc Imaging
. 2019
;35
(12
):2197
–203
. .© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
